CASI Pharmaceuticals (NASDAQ:CASI) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI) in a report issued on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.

CASI Pharmaceuticals Stock Performance

Shares of NASDAQ CASI opened at $2.30 on Wednesday. The stock has a fifty day moving average price of $2.44 and a two-hundred day moving average price of $4.10. The company has a debt-to-equity ratio of 1.38, a quick ratio of 2.32 and a current ratio of 3.20. The firm has a market cap of $35.63 million, a P/E ratio of -1.03 and a beta of 0.41. CASI Pharmaceuticals has a 1 year low of $2.04 and a 1 year high of $7.67.

Institutional Investors Weigh In On CASI Pharmaceuticals

An institutional investor recently bought a new position in CASI Pharmaceuticals stock. Foresite Capital Management VI LLC acquired a new position in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,329,383 shares of the biotechnology company’s stock, valued at approximately $3,762,000. CASI Pharmaceuticals makes up approximately 1.7% of Foresite Capital Management VI LLC’s portfolio, making the stock its 13th biggest holding. Foresite Capital Management VI LLC owned 8.58% of CASI Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 22.23% of the company’s stock.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.